China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

Illumina (ILMN) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a ...

a Hong Kong-based investment firm backed by Alibaba co-founder Joe Tsai, in exchange for a 12 per cent stake. Inside Retail spoke with Mauro Maggioni, Golden Goose’s Apac CEO, about how the business ...

Harmonized regulations for laboratory-developed tests (LDTs) across Asia Pacific are sorely needed at a time when LDTs continue to play a critical role in addressing unmet needs in the region, ...

Illumina (ILMN) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

Growing Research & Development Activities: Driving the Ewing’s Sarcoma Market The market for Ewing’s sarcoma is expanding due in large part to the increased emphasis on research and development (R&D) ...

While the U.S. Supreme Court sidelined itself over patent issues such as subject matter eligibility, the diagnostic patent wars are still in full swing as a casual review of cases at the U.S. Patent ...